Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects.

Next Previous
Trial Profile

Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Abatacept (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov
    • 12 Jun 2012 3-year follow-up results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top